Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 10 months ago

Anticoagulation
Timing of SGLT2 Inhibitors in Heart Failure
Author(s): Moritake Iguchi , Hiromichi Wada , Felipe Martínez , et al Added: 1 year ago

Heart Failure

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 9 months ago

Anticoagulation
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 1 year ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 1 month ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation
What’s New in the European ACS Guidelines and How Will My Practice Change?
Author(s): Robert F Storey , Dominick J Angiolillo , Christopher P Cannon , et al Added: 1 year ago
Led byProf Robert Storey (University of Sheffield, Sheffield, UK), this on-demand version of the live broadcast delves into the2023 ACS guideline updates that were recently presented at the European Society of Cardiology (ESC) annual meeting in Amsterdam. Join the conversation withDr Dominick Angiolillo (University of Florida, Gainesville, US), Dr Christopher Cannon (Brigham and Women's… View more

Anticoagulation

Guidelines & Statements
Prognostic Utility of the ABCD-GENE Score in Asian ACS Patients
Author(s): Cheng Keat Tan , David Bin-Chia Wu , Seh Yi Joseph Tan , et al Added: 1 year ago

Anticoagulation

MI/ACS
Factor XI Inhibition and AF
Author(s): Bianca Rocca , Hugo ten Cate Added: 1 month ago

Anticoagulation

Electrophysiology & Arrhythmia
HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in symptomatic nHCM
Author(s): Ahmad Masri Added: 1 year ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826). This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that… View more

Heart Failure
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 1 month ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions